selective factor B serine protease inhibitor
orally available, retinal barrier penetrant
J. Med. Chem., Feb. 19, 2020
Novartis (NIBR), Cambridge, MA
LNP023
February’s molecule, the Novartis factor B inhibitor LNP023, targets the serine protease factor B (FB), a key node in the complement system. The complement part of the innate immune system is…